BioCentury | Nov 22, 2019
Finance

Syncona backs Cambridge oncology spinout Azeria in £32M series B

Syncona is taking a majority stake in University of Cambridge spinout Azeria by leading the company's £32 million ($41.5 million) series B round, with which the start-up hopes to bring its first FOXA1 inhibitor into...
BioCentury | Nov 21, 2019
Clinical News

Syncona backs Cambridge oncology spinout Azeria in £32M series B

Syncona is taking a majority stake in University of Cambridge spinout Azeria by leading the company's £32 million ($41.5 million) series B round, with which the start-up hopes to bring its first FOXA1 inhibitor into...
BioCentury | Feb 1, 2019
Product R&D

BlueRock’s PD purity play

...intermediate known as the floor plate midbrain progenitor cell, which expresses the markers LMX1A and FOXA2...
...neurotransmitter transporter dopamine member 3 LMX1A (LMX1) - LIM homeobox transcription factor 1α FOXA2 - Forkhead box A2...
BioCentury | Jan 17, 2018
Distillery Therapeutics

Neurology

...and rat studies suggest co-transplantation of neural progenitor cells (NPCs) and astrocytes expressing NURR1 and FOXA2...
...death compared with NPCs alone, and co-culture with the astrocytes engineered to overexpress NURR1 and FOXA2...
...In a rat model of PD, intrastriatal co-transplantation of the NPCs and the NURR1- and FOXA2-overexpressing...
BioCentury | Jan 11, 2018
Translation in Brief

Astrocytes on the mind

...towards the neuroprotective phenotype: nuclear receptor subfamily 4 group A member 2 (NURR1; NR4A2) and forkhead box A2 (FOXA2)...
...co-cultured ventral midbrain NPCs with astrocytes from the same region engineered to overexpress NURR1 and FOXA2...
...unmodified astrocytes. In a rat model of PD, intrastriatal transplantation of NPCs and NURR1- and FOXA2-overexpressing...
BioCentury | Dec 11, 2017
Preclinical News

Histone modifier is implicated in epithelial-mesenchymal transition

In a paper published in the Journal of Cell Biology , researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) identified a histone modifier that may regulate epithelial-mesenchymal transition (EMT), a process associated with tumor...
BioCentury | Sep 19, 2017
Distillery Therapeutics

Neurology

...cells as floating spheres from days 12 to 28, after which dopaminergic neurons positive for forkhead box A2 (FOXA2)...
BioCentury | Jun 16, 2016
Distillery Therapeutics

Therapeutics: Forkhead box A1 (FOXA1); FOXA2; FOXA3; GATA binding protein 4 (GATA4); HNF1 homeobox A (HNF1A); hepatocyte nuclear factor 4 α (HNF4A; TCF) FOXA3,

...vivo transduction of myofibroblasts with six adeno-associated virus serotype 6 (AAV6) vectors encoding FOXA1 , FOXA2...
...developing vectors with improved in vivo myofibroblast transduction efficiency. TARGET/MARKER/PATHWAY: Forkhead box A1 (FOXA1) ; FOXA2...
BioCentury | Nov 20, 2014
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers SNPs near the gene encoding estrogen receptor-a for predicting breast cancer risk in Latina women Genetic variants near the gene encoding estrogen receptor-a could help predict...
BioCentury | Mar 20, 2014
Cover Story

A liver divided

Three separate teams have directly converted human fibroblasts to proliferative liver cells and thus eliminated a key drawback of using induced pluripotent stem cells to treat damaged livers-the inability of the resulting differentiated cells to...
Items per page:
1 - 10 of 18